Clinical trials
Gastrointestinal Neoplasms trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
62 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 4 |
| 2016 | 2 |
| 2017 | 4 |
| 2019 | 4 |
| 2020 | 6 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 9 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Recruiting | 19 |
| Terminated | 6 |
| Not yet recruiting | 6 |
| Active, not recruiting | 5 |
| Unknown status | 3 |
| Withdrawn | 2 |
| Approved for marketing | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hospices Civils de Lyon | 5 |
| Assistance Publique - Hôpitaux de Paris | 3 |
| Institut du Cancer de Montpellier - Val d'Aurelle | 3 |
| Boehringer Ingelheim | 2 |
| GERCOR - Multidisciplinary Oncology Cooperative Group | 2 |
| GlaxoSmithKline | 2 |
| Hoffmann-La Roche | 2 |
| Institut Cancerologie de l'Ouest | 2 |
| Merck Sharp & Dohme LLC | 2 |
| Pfizer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gastrointestinal Neoplasms | 62 |
| Colorectal Neoplasms | 16 |
| Neoplasms | 13 |
| Lung Neoplasms | 9 |
| Pancreatic Neoplasms | 9 |
| Neoplasms by Site | 8 |
| Breast Neoplasms | 7 |
| Intestinal Neoplasms | 7 |
| Neoplasm Metastasis | 7 |
| Carcinoma, Non-Small-Cell Lung | 6 |
Trials
Showing 51 to 62 of 62. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.